Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2010; 16(46): 5830-5837
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5830
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5830
Table 6 Occurrence of the wt and mutated form of the peroxisome proliferator-activated receptor-γ2 depending on the grade of inflammation and fibrosis n (%)
Inflammation | Fibrosis | |||||||||||
NAFLD | AFLD | NAFLD | AFLD | |||||||||
Total | Moderate (0-1) | Severe (2-3) | Total | Moderate (0-1) | Severe (2-3) | Total | F0-F1 | F2-F4 | Total | F0-F1 | F2-F4 | |
Allelic discrimination | ||||||||||||
Mutation | 66 (100) | 38 (58) | 28 (42) | 26 (100) | 9 (35) | 17 (65) | 66 (100) | 47 (71) | 19 (29) | 26 (100) | 4 (15) | 22 (85) |
Wild type | 460 (100) | 296 (64) | 164 (36) | 174 (100) | 99 (57) | 75 (43) | 460 (100) | 327 (71) | 133 (29) | 174 (100) | 54 (31) | 120 (69) |
P value | 0.175 | 0.028 | 0.555 | 0.075 | ||||||||
Odds ratio (CI) | 1.33 (0.79-2.25) | 2.50 (1.05-5.90) | 0.99 (0.56-1.76) | 2.48 (0.81-7.53) |
- Citation: Rey JW, Noetel A, Hardt A, Canbay A, Alakus H, Hausen AZ, Dienes HP, Drebber U, Odenthal M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases. World J Gastroenterol 2010; 16(46): 5830-5837
- URL: https://www.wjgnet.com/1007-9327/full/v16/i46/5830.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i46.5830